KRAS and neuroblastoma: Our study demonstrates that a potent SETD8 inhibitor with enhanced activity and selectivity, SGSS05-NS3 rescues the canonical p53 functions, restores p53-mediated DNA damage response, in pre-clinical xenograft NB models confers a significant survival advantage in MYCN-WT NB.